May 9 (Reuters) - Shattuck Labs Inc STTK.O :
* SHATTUCK LABS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
AND
RECENT BUSINESS HIGHLIGHTS
* SHATTUCK LABS-CASH, CASH EQUIVALENTS & INVESTMENTS TO BE
SUFFICIENT TO FUND OPERATIONS THROUGH YEAR-END 2024, BEYOND
RESULTS FROM PHASE 1 CLINICAL TRIALS OF SL-172154
* QTRLY LOSS PER SHARE $0.49
* Q1 EARNINGS PER SHARE VIEW $-0.63 -- REFINITIV IBES DATA
* AS OF MARCH 31, 2023, CASH AND CASH EQUIVALENTS AND
INVESTMENTS
WERE $135.5 MILLION
Source text for Eikon: ID:nGNX1GynsB
Further company coverage: STTK.O
((Reuters.Briefs@thomsonreuters.com;))